In the latest close session, Hims & Hers Health, Inc. (HIMS) was down 1.73% at $32.96. The stock's performance was behind the S&P 500's daily loss of 1.44%. On the other hand, the Dow registered a ...

Hims & Hers Health, Inc. (HIMS) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

Throughout 2024, Hims & Hers demonstrated consistent top-line acceleration driven by new product introductions and broader consumer adoption. The company’s revenue grew from $260 million in Q1 2024 to ...

Learn more Leerink maintained a 'Market Perform' rating and a $25 price target, implying a 10% downside from current levels.

Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $27.71, moving -4.38% from the previous trading session. This change lagged the S&P 500's 1.62% loss on the day. Meanwhile, the ...

Photo illustration of Wegovy and a weight scale. Wegovy is an injectable prescription weight loss medicine that has helped people with obesity. It should be used with a weight loss plan and physical ...

Hims & Hers Health (NYSE: HIMS), a telehealth platform, saw its stock surge 8% on Friday, May 30th, following the announcement of a 4% workforce reduction. This adjustment comes as the company adapts ...

We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you ...

HIMS is expanding into hormone health and diagnostics to deepen subscriber value and care personalization. GDRX is growing pharma-manufacturer services and retail integrations to enhance transparency ...

Hims & Hers Health, Inc. HIMS is scheduled to report third-quarter 2025 results on Nov. 3, after the closing bell. In the last reported quarter, the company’s earnings per share (EPS) of 17 cents ...

Hims & Hers Health (NYSE:HIMS) is set to report its earnings on Monday, Feb 24 after market close. HIMS stock plunged over 25% on Friday, Feb 21, after the U.S. FDA announced semaglutide is no longer ...